Investors
Building the future of bioprocessing
Qualified investor enquiries welcome. We welcome discussions with investors aligned with early-stage deeptech and biotech.
Road Map
Key milestones ahead
2025
Fundraising and first partnerships
2027
Handling of our first preclinical batches
2028
Pilot scale: Handling of our first clinical batches
2029
Development of first commercial-scale equipment
2030
Sale of first equipment
2032
Investor exit via a strategic or financial buyer
Investment Thesis
Why Askleia
Four interlocking reasons why Askleia is building in the right space, with the right approach, at the right time.
1
The market is large and growing
The global biopharma downstream processing market exceeds $10Bn and continues to expand as new biomolecule-based therapies reach clinical development. Purification represents 40–60% of total manufacturing cost for many biologics.
2
The problem is real and persistent
Despite decades of chromatographic purification as standard, the field remains characterised by high consumable costs, batch-mode constraints, and significant process development overhead.
3
Askleia's technology is genuinely different
Not an optimisation of existing methods — a breakthrough innovation. We offer equipment and services based on the principle of electrophoresis, which enables the separation of biological molecules that chromatography is not always able to achieve.
4
The timing is right
Continuous bioprocessing adoption, cost pressure from biosimilar competition, and regulatory openness to novel processes are converging to create a window for technology adoption.
Investor Contact
Get in touch
Detailed materials are available under NDA.
Contact :
Hours: 9 a.m. – 5 p.m., Monday to Friday
Phone: +33 4 42 01 90 59
Address: 510 Avenue de Jouques, Pôle Performance, Building C2, 13400 Aubagne
